Community Research and Development Information Service - CORDIS


GENE — Result In Brief

Project ID: 328695
Funded under: FP7-PEOPLE
Country: Netherlands

Targeting tumour blood vessels

Tumour growth can be inhibited by targeting its blood supply. Finding new targets in the tumour blood vessels could help to develop specific anti-cancer drugs.
Targeting tumour blood vessels
Tumour cells require oxygen and nutrients to be able to grow and therefore a tumour induces the formation of new blood vessels. This process of formation of new blood vessels from pre-existing vasculature is called angiogenesis.

Several anti-angiogenic drugs are currently available for the treatment of cancer. Most of them target the tumour’s angiogenic factors and their efficiency is often diminished by the development of resistance to treatment with these drugs. The aim of the EU-funded GENE (Genomic screening of the embryo for novel targets in the tumour endothelium) was to find specific markers of tumour endothelial cells, the cells lining the inner of the tumour blood vessels, to be able to specifically target the tumour blood vessels with drugs.

The working hypothesis of the project was based on the idea that genes that are functional during embryonic development might be also active in the tumour vasculature. The researchers analysed the full expression profile of mouse embryos at different stages of development as well as that of tumour endothelial cells. They used adult mouse tissues for comparison to identify the genes that are specific for embryos.

Screening identified 24 candidate genes, which had 100-fold higher expression in tumour endothelial cells in comparison to the adult mouse tissues. Researchers validated the tissue expression of the 10 most promising extracellularly expressed candidate genes.

Research work by the GENE project represents an important initial stage of the development of novel and potentially highly efficient anti-cancer drugs. The identified targets are specific to the tumour endothelial cell, a feature which will minimise potential toxic side effects and reduces the possibility of tumour cell mutation into drug resistant variants.

Related information


Tumour, blood vessels, anti-cancer drugs, endothelial cell, embryonic development
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top